Literature DB >> 22056245

Tilting the AXIS towards therapeutic limits in renal cancer.

Axel Bex1, John Haanen.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22056245     DOI： 10.1016/S0140-6736(11)61655-3

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  3 in total

Review 1.  Immunological heterogeneity of the RCC microenvironment: do targeted therapies influence immune response?

Authors:  Axel Bex; Tamara Etto; Florry Vyth-Dreese; Christian Blank; Arjan W Griffioen
Journal:  Curr Oncol Rep       Date:  2012-06       Impact factor: 5.075

Review 2.  A comprehensive overview of targeted therapy in metastatic renal cell carcinoma.

Authors:  Z Mihaly; Z Sztupinszki; P Surowiak; B Gyorffy
Journal:  Curr Cancer Drug Targets       Date:  2012-09       Impact factor: 3.428

3.  Response to post-axitinib treatment in patients with metastatic renal cell carcinoma.

Authors:  Namita Chittoria; Housam Haddad; Paul Elson; Nizar M Tannir; Laura S Wood; Robert Dreicer; Jorge A Garcia; Brian I Rini; Eric Jonasch
Journal:  BMC Cancer       Date:  2016-03-29       Impact factor: 4.430
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.